|
|
1.
|
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. MedStar authors:
Year: 2017
Citation: - Lancet Oncology. 18(11):1493-1501, 2017 Nov
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Attia S, Baker LH, Bolejack V, Burgess M, Butterfield LH, Crowley J, D'Angelo S, Davis LE, Hu J, Lazar AJ, Maki RG, Movva S, Okuno SH, Patel S, Priebat DA, Reed DR, Reinke D, Riedel RF, Rodriguez-Canales J, Salazar R, Schuetze SM, Tawbi HA, Van Tine BA, Wistuba II
|
|
|
2.
|
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. MedStar authors:
Year: 2017
Citation: - Lancet Oncology. 18(12):1600-1609, 2017 Dec
Institution: - MedStar Franklin Square Hospital
Medline publication type:
All authors: - Brahmer JR, Csoszi T, Cuffe S, Deitz AC, Fulop A, Gottfried M, Hotta K, Hui R, Lubiniecki GM, O'Brien M, Peled N, Rangwala R, Rao S, Reck M, Robinson AG, Rodriguez-Abreu D, Tafreshi A, Zhang J
|
